Activity Dates: 04/08/2019 - 10/10/2019
This activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.
The Clinical Application Series is an application-based continuing pharmacy education (CPE) activity designed to improve competency of partcipants. An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned at the current level of practice by Board Certified Psychiatric Pharmacists. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings.
The Clinical Application Series includes:
To satisfactorily complete the Clinical Application Series and receive 5 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Marilyn N. Bulloch, PharmD, BCPS, FCCM
Michael O. Measom, MD
Katharine J. Nelson, MD, FAPA
Russell Spieth, PhD, CRC
Steven Clark Stoner, PharmD, BCPP
Presented Sunday, April 7, 2019 at CPNP Annual Meeting Recertification Programming |
---|
Topic |
Overcoming Barriers to Excellent Pharmacologic Treatment of Borderline Personality Disorder (BPD) ACPE #: 0284-0000-19-002-L01-P (Application) Speaker: Katharine J. Nelson, MD, FAPA Learning Objectives:
|
Improving Medication Non-Adherence via Motivational Interviewing ACPE #: 0284-0000-19-003-L04-P (Application)Speaker: Russell Spieth, PhD, CRC Learning Objectives:
|
Tardive Dyskinesia (TD): Identification and Management ACPE #: 0284-0000-19-004-L01-P (Application) Speaker: Steven Clark Stoner, PharmD, BCPP Learning Objectives:
|
Presented Monday, April 8, 2019 at CPNP Annual Meeting |
Topic |
Management of Narcolepsy ACPE #: 0284-0000-19-005-L01-P (Application) Speaker: Marilyn N. Bulloch, PharmD, BCPS, FCCM Learning Objectives:
|
Medication Adherence in the Digital Age: Incorporating Technology, Shared Decision Making, and Ethical Considerations ACPE #: 0284-0000-19-006-L04-P (Application) Speaker: Michael O. Measom, MD Learning Objectives:
|
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2019 CPNP Recertification Editorial Board Disclosures
Mary C. Borovicka, PharmD, BCPP, BCPS Associate Professor University of Toledo College of Pharmacy and Pharmaceutical Sciences Cleveland, OH No Relevant Financial Relationships to Disclose |
Beth DeJongh, PharmD, BCPP, BCPS Recertification Editorial Board Vice Chair Pharmacist Concordia University Wisconsin Mequon, WI No Relevant Financial Relationships to Disclose |
Sara E. Dugan, PharmD, BCPP, BCPS Associate Professor Northeast Ohio Medical University College of Pharmacy and Medicine Rootstown, OH No Relevant Financial Relationships to Disclose |
Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
Clayton D. English, PharmD, BCPP, BCPS |
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA No Relevant Financial Relationships to Disclose |
Jessica L. Goren, PharmD, BCPP Senior Pharmacist Specialist Cambridge Health Alliance Cambridge, MA Educational Grants, Research Grants or Contracts: VA Grant funding-ended 2017 Non-Financial Interests: past BPS psychiatry council member and chair |
Rebecca Graham, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health Corporal Michael J. Crescenz VA Medical Center in Philadelphia Philadelphia, PA No Relevant Financial Relationships to Disclose |
Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO |
Rex S. Lott, PharmD, BCPP BCPP Program Director Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
Monica Mathys, PharmD, BCPP Associate Professor Texas Tech Health Sciences Dallas, TX No Relevant Financial Relationships to Disclose |
Sarah T. Melton, PharmD, BCPP, BCACP, FASCP |
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL Educational Grants, Research Grants or Contracts: Agency for Health Care Administration |
Jessica L. Mulhollan, PharmD, BCPP Psychiatric Clinical Pharmacy Specialist Cleveland Clinic Marymount Hospital Garfield Heights, OH No Relevant Financial Relationships to Disclose |
Sandra Mullen, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry VCU Health Systems Richmond, VA Non-Financial Interests: Lambda Kappa Sigma Grand Council (Executive Board) |
Stephanie Nichols, PharmD, BCPP, BCPS Associate Professor of Pharmacy Practice Husson University Bangor, ME Non-Financial Interests: Member of the New England Comparative Effectiveness Public Advisory Committee of the Institute for Clinical and Economic Review, Maine Independent Clinical Information Service Academic Detailing Advisory Committee |
Sarah J. Popish, PharmD, BCPP Academic Educator Department of Veterans Affairs Vallejo, CA No Relevant Financial Relationships to Disclose |
Megan M. Sarashinsky, PharmD, BCPP Clinical Pharmacy Specialist CJW Medical Center Richmond, VA No Relevant Financial Relationships to Disclose |
Andrew M. Williams, PharmD, BCPP, BCGP Clinical Pharmacist Riverside University Health System Riverside, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Amgen Inc: Received compensation for consultant and speaking activities |
Andrea Winterswyk, PharmD, BCPS, BCPP Mental Health Clinical Pharmacy Specialist Boise Veterans Affairs Medical Center Boise, ID No Relevant Financial Relationships to Disclose |
Kara R. Wong, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health; PGY2 Psychiatric Pharmacy Residency Program Director Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.